title: What is the role of bosentan in healing of femur fractures in a rat model?
abstract: The purpose of this study was to examine the effects bosentan (which is a strong vasoconstrictor) on bone fracture pathophysiology, and investigate the roles of the nonselective endothelin 1 receptor blocker bosentan on the bone fractures formed in rats through radiographic, histopathologic, and immunohistochemical methods. The rats were divided into three groups (six rats in each group): a femoral fracture control group, a femoral fracture plus bosentan at 50 mg/kg group, and a femoral fracture plus bosentan at 100 mg/kg group. The femoral fracture model was established by transversely cutting the femur at the midsection. After manual reduction, the fractured femur was fixed with intramedullary Kirschner wires. The radiographic healing scores of the bosentan 100 and 50 mg/kg groups were significantly better that those of the fracture control group. The fracture callus percent of new bone in the bosentan 100 mg/kg group was significantly greater than that in the control group. Also, semiquantitative analysis showed higher positive vascular endothelial growth factor and osteocalcin staining and lower positive endothelin receptor type A staining in the treatment groups than in the control group. Bosentan treatment also decreased tissue endothelin 1 expression relative to that in the fracture control group. As a result of our study, the protective effect of bosentan was shown in experimental femoral fracture healing in rats by radiographic, histopathologic, and molecular analyses.
authors.affiliation: Department of Orthopedics and Traumatology, Ataturk University Faculty of Medicine, 25240, Erzurum, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Aydin
authors.forename: Zekai
authors.initials: Z
authors.lastname: Halici
authors.forename: Erol
authors.initials: E
authors.lastname: Akpinar
authors.forename: A Murat
authors.initials: AM
authors.lastname: Aksakal
authors.forename: Murat
authors.initials: M
authors.lastname: Saritemur
authors.forename: Muhammed
authors.initials: M
authors.lastname: Yayla
authors.forename: C Semih
authors.initials: CS
authors.lastname: Kunak
authors.forename: Elif
authors.initials: E
authors.lastname: Cadirci
authors.forename: H Tarik
authors.initials: HT
authors.lastname: Atmaca
authors.forename: S Sena
authors.initials: SS
authors.lastname: Karcioglu
mesh_terms: D000818:Animals; D002146:Bony Callus / Q000187:drug effects / Q000378:metabolism; D000077300:Bosentan; D004195:Disease Models, Animal; D005264:Femoral Fractures / Q000188:drug therapy* / Q000378:metabolism; D005269:Femur / Q000187:drug effects* / Q000378:metabolism; D017102:Fracture Healing / Q000187:drug effects*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D013449:Sulfonamides; D042461:Vascular Endothelial Growth Factor A; D000077300:Bosentan